Related Experiment Video
Updated: May 26, 2026
10:08
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
Published on: November 22, 2024
FTO gene polymorphisms and platelet counts in a general Japanese population
Kazuhiko Kotani1, Shinji Fujiwara, Kokoro Tsuzaki
1Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. kazukotani@jichi.ac.jp
Summary
The fat mass and obesity-associated (FTO) gene influences platelet counts. FTO gene variations are linked to higher platelet levels in Japanese adults, independent of obesity markers.
Area of Science:
- Genetics and Genomics
- Hematology
- Metabolic Disorders
Background:
- The fat mass and obesity-associated (FTO) gene is recognized for its role in obesity.
- Obesity-related gene polymorphisms are implicated in atherothrombosis, particularly concerning platelet function.
- Platelets play a crucial role in thrombotic processes.
Purpose of the Study:
- To investigate the association between FTO gene polymorphisms (rs1558902, T/A) and hematological parameters, specifically platelet counts.
- To determine if FTO gene variations influence platelet counts in an asymptomatic Japanese population.
Main Methods:
- Genotyping of FTO gene polymorphisms (rs1558902, T/A) using an allele-specific DNA assay.
- Measurement of anthropometric, hematological, and biochemical parameters in 209 Japanese subjects.
- Statistical analysis including multiple adjustments for confounding variables.
Main Results:
- Subjects with the A-allele of the FTO gene (n=73) exhibited significantly higher platelet counts compared to those without the A-allele (237 [58] vs 217 [57] × 10/L, P < 0.05).
- This association remained significant and independent of obesity-related parameters like insulin resistance and high-sensitivity C-reactive protein after multiple adjustments.
- FTO gene polymorphisms showed a significant, albeit minor, modulation of platelet counts.
Conclusions:
- FTO gene polymorphisms are associated with variations in platelet counts in the studied Japanese population.
- These findings suggest a potential genetic link between FTO, platelet modulation, and possibly atherothrombosis risk.
- Further research is warranted to elucidate the mechanisms underlying FTO's influence on platelet parameters.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...